Niraparib,abiraterone,Prednisone
Janssen
['brca', 'niraparib', 'prostate', ' nira ', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
with a longer median follow-up of 26.8 months, magnitude confirms the benefit of the
nira + aap combination, with a 45% reduction in the risk of progression or death and extension of the median rpfs to &gt;1.5 years at la2 compared with placebo + aap. #gu23 #prostatecancer 
Jefe de Servicio de Oncología Médica. Hospital Universitario Lucus Augusti, HULA. Grupo de Investigación Oncológica Traslacional, GIOT HULA. Cuenta personal